AssayIndex
Reports by quarter

Reports submitted in 2024-Q4

Impurity-fingerprint matching introduced; first shared-bulk links published. Median purity for the quarter is 99.09 % area, n=416. Read the 2024-Q4 state-of-the-index report →

416 records11 pagesmedian on this page 99.11 %updated 30 Jul 2026
022446692.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=297.00–97.25 %: n=397.25–97.50 %: n=397.50–97.75 %: n=1097.75–98.00 %: n=1598.00–98.25 %: n=2098.25–98.50 %: n=3698.50–98.75 %: n=3798.75–99.00 %: n=5199.00–99.25 %: n=7699.25–99.50 %: n=5899.50–99.75 %: n=4799.75–100.00 %: n=58median 99.09 Purity (% area) Reports
Figure. Purity distribution for reports submitted in 2024-Q4. n=416, median 99.09 % area. Same fixed 92–100 % domain as every other purity histogram on this site, so quarters can be compared by eye.
ReportCompoundSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2025-019400Enclomiphene citrateHYBHYB-2408-N7131Janoshik2024-Q499.702.10104.5Buyer-sourced0FAIL
AX-2025-021236Melanotan IIPPGPPG-2408-L8298Janoshik2024-Q499.914.4493.5Laboratory-retained0PASS
AX-2025-019218RetatrutideSinoPepSNP-2405-T4694Kestrel2024-Q498.864.07102.8Supplier-supplied0PASS
AX-2025-019833SurvodutideHomopeptideHOMO-2406-F5091PeptideMeter2024-Q499.325.1799.3Buyer-sourced0PASS
AX-2025-021237Melanotan IIPPGPPG-2408-L8298VendorInvestigate2024-Q499.784.3291.4Buyer-sourced0PASS
AX-2025-019832SurvodutideHomopeptideHOMO-2406-F5091Nordanalyt2024-Q499.144.78—Buyer-sourced0PASS
AX-2025-021111TirzepatideQSTQST-2409-K5786Nordanalyt2024-Q498.846.4589.5Supplier-supplied1MARGINAL
AX-2025-021003MK-677 (Ibutamoren mesylate)WXTWXT-2408-P3767PeptideMeter2024-Q499.124.55—Buyer-sourced1FAIL
AX-2025-019868RetatrutideHJHJ-2411-M5834Janoshik2024-Q498.296.3893.1Buyer-sourced0PASS
AX-2025-020537SemaxSSASSA-2410-G6492Medutest2024-Q497.879.8798.5Buyer-sourced0FAIL
AX-2025-020232SermorelinGGPepsGGPE-2409-C1458Medutest2024-Q498.496.4191.8Buyer-sourced0PASS
AX-2025-021182GHRP-6PPGPPG-2405-W6859PeptideMeter2024-Q499.934.3288.6Laboratory-retained1MARGINAL
AX-2025-020793Kisspeptin-10CPCCPC-2411-W9644Nordanalyt2024-Q498.623.7391.8Buyer-sourced0PASS
AX-2025-020682TirzepatideSGNSGN-2411-N9012Janoshik2024-Q498.813.06—Buyer-sourced0PASS
AX-2025-019860SS-31 (Elamipretide)HomopeptideHOMO-2410-K5866Janoshik2024-Q499.913.3492.2Buyer-sourced0PASS
AX-2025-018526SurvodutideWWBWWB-2408-T3710Janoshik2024-Q499.303.29106.2Buyer-sourced0PASS
AX-2025-021183GHRP-6PPGPPG-2405-W6859PeptideMeter2024-Q499.524.5899.0Buyer-sourced0PASS
AX-2025-019861SS-31 (Elamipretide)HomopeptideHOMO-2410-K5866Medutest2024-Q499.933.33—Buyer-sourced0PASS
AX-2025-019705SemaglutideTFCTFC-2409-S3094Janoshik2024-Q498.853.41100.2Buyer-sourced0PASS
AX-2025-020697L-Glutathione (reduced)SGNSGN-2410-P9125Kestrel2024-Q499.4910.77—Buyer-sourced0PASS
AX-2025-021112TirzepatideQSTQST-2409-K5786Janoshik2024-Q498.025.7898.6Buyer-sourced0PASS
AX-2025-021106CJC-1295 with DACBCHBCH-2406-E5279Janoshik2024-Q498.464.8095.1Buyer-sourced1MARGINAL
AX-2025-020538SemaxSSASSA-2410-G6492PeptideMeter2024-Q498.6810.1395.6Buyer-sourced0PASS
AX-2025-019703RetatrutideTFCTFC-2409-H3000Janoshik2024-Q497.263.84—Buyer-sourced1MARGINAL
AX-2025-019776PT-141 (Bremelanotide)HomopeptideHOMO-2408-P4132Janoshik2024-Q499.931.71—Laboratory-retained0PASS
AX-2025-021004MK-677 (Ibutamoren mesylate)WXTWXT-2408-P3767Janoshik2024-Q499.104.9291.6Supplier-supplied1FAIL
AX-2025-020169NAD+ERPERP-2405-P9008Janoshik2024-Q497.829.0595.5Buyer-sourced0PASS
AX-2025-019286SemaxAMBAMB-2411-G5528Medutest2024-Q499.539.78—Buyer-sourced0PASS
AX-2025-019056Kisspeptin-10ASYASY-{CAT}-2919Medutest2024-Q499.935.85—Buyer-sourced0PASS
AX-2025-020698TirzepatideSGNSGN-2408-S8580Janoshik2024-Q498.193.26—Buyer-sourced1MARGINAL
AX-2025-020233SermorelinGGPepsGGPE-2409-C1458VendorInvestigate2024-Q498.386.1891.8Buyer-sourced0PASS
AX-2025-019834SurvodutideHomopeptideHOMO-2406-F5091Janoshik2024-Q499.704.8696.5Buyer-sourced0PASS
AX-2025-019353SemaglutideHYBHYB-2407-V6435Janoshik2024-Q498.764.67—Buyer-sourced0PASS
AX-2025-020653SemaglutideSGNSGN-2409-F8056PeptideMeter2024-Q498.223.9091.9Buyer-sourced0PASS
AX-2025-020612TB-500SSASSA-2406-H7589PeptideMeter2024-Q499.284.7391.5Supplier-supplied0PASS
AX-2025-020212RetatrutideGGPepsGGPE-2411-R9634PeptideMeter2024-Q499.184.86—Buyer-sourced0PASS
AX-2025-019152LL-37GSPGSP-2410-U4092Janoshik2024-Q498.305.48102.5Buyer-sourced0PASS
AX-2025-019862SS-31 (Elamipretide)HomopeptideHOMO-2410-K5866PeptideMeter2024-Q499.713.44106.1Buyer-sourced0PASS
AX-2025-019339BPC-157HYBHYB-2409-X6061PeptideMeter2024-Q499.073.80106.2Buyer-sourced1MARGINAL
AX-2025-0189325-Amino-1MQTFSTFS-{CAT}-1476Janoshik2024-Q499.935.15—Buyer-sourced0FAIL